View Older Stories View More Recent Stories

Nov 5, 2024 07:29AM Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Oct 31, 2024 07:30AM Organon Reports Results for the Third Quarter Ended September 30, 2024
Oct 30, 2024 06:05AM Organon (OGN) Announces FDA Acceptance of BLA for HLX14
Oct 30, 2024 06:00AM US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
Oct 28, 2024 09:25AM Organon (OGN) Completes Acquisition of Dermavant
Oct 28, 2024 09:25AM Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Oct 9, 2024 07:30AM Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
Sep 30, 2024 06:06AM Organon (OGN) Reports Primary Endpoint Met in Phase 3 Comparative Clinical Study of HLX11
Sep 30, 2024 06:00AM Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Sep 18, 2024 07:30AM Organon (OGN) to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1%
Sep 18, 2024 07:30AM Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Aug 20, 2024 07:31AM Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
Aug 20, 2024 07:30AM Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Aug 6, 2024 07:30AM Organon Reports Results for the Second Quarter Ended June 30, 2024
Jul 9, 2024 07:30AM Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
May 24, 2024 06:01AM Organon (OGN) Announces EMA Validated Filings for HLX14
May 24, 2024 06:00AM European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 8, 2024 05:46AM Organon (OGN) Prices $1B Notes Offering
May 7, 2024 08:20PM Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 7, 2024 08:00AM Organon (OGN) Announces Proposed $1B Senior Notes Offering
May 7, 2024 07:58AM Organon Announces Proposed $1.0 Billion Senior Notes Offering
May 2, 2024 07:30AM Organon Reports Results for the First Quarter Ended March 31, 2024
Apr 8, 2024 06:15AM Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Apr 8, 2024 06:00AM Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Feb 20, 2024 08:03AM Organon (OGN) Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
Feb 20, 2024 08:00AM Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
Feb 15, 2024 07:30AM Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb 1, 2024 07:30AM Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
Jan 10, 2024 07:33AM Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
Jan 8, 2024 07:32AM Organon (OGN) Affirms 2023 Guidance, Issues 2024 Outlook
Jan 8, 2024 07:30AM Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
Dec 21, 2023 07:30AM Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 18, 2023 07:31AM Organon (OGN) and Eli Lilly (LLY) Enter Commercialization Agreement in Europe for Two Migraine Medicines
Dec 18, 2023 07:30AM Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Nov 21, 2023 07:30AM Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
Nov 7, 2023 04:16PM Organon (OGN) and Samsung Bioepis Announce FDA Acceptance of sBLA for Interchangeability Designation for HADLIMA
Nov 7, 2023 04:15PM Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
Nov 7, 2023 04:15PM Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
Nov 2, 2023 07:30AM Organon Reports Results for the Third Quarter Ended September 30, 2023
Nov 1, 2023 07:30AM Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
Oct 19, 2023 07:30AM Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
Sep 27, 2023 07:30AM Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
Sep 14, 2023 05:12PM First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
Sep 5, 2023 10:01AM Organon (OGN) Appoints Juan Camilo Arjona Ferreira as Chief Medical Officer, Charlotte Owens as Head of Medical Affairs and Outcomes Research
Sep 5, 2023 10:00AM Organon Bolsters Research & Development Expertise with Two Leadership Appointments
Aug 8, 2023 07:30AM Organon Reports Results for the Second Quarter Ended June 30, 2023
Aug 1, 2023 07:02AM Organon (OGN) and Samsung Bioepis Report Topline Results from Interchangeability Study of SB5 Humira Biosimilar
Aug 1, 2023 07:00AM Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
Aug 1, 2023 07:00AM Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
Jul 17, 2023 07:30AM Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
View More Recent Stories View Older Stories